ArticlePloS one2026
Evaluation of outcomes in 201 child and youth survivors of Child Sexual Abuse (CSA) who participated in a one-year multimodal treatment program.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and rationaleChild sexual abuse (CSA) is a pervasive and prevalent form of early-life trauma that can increase the risk for PTSD, mood disorders, substance abuse, harmful behaviour, non-suicidal self-harm, suicidal ideation, and death by suicide. Preliminary research has shown positive impacts of multimodal treatment for youth survivors of CSA, but no 'gold-standard' currently exists for CSA treatment. The aim of this study was to provide a secondary analysis of data from a longitudinal, episodic, and multimodal treatment program specifically designed to treat child and adolescent survivors of CSA.
methodsChild and youth survivors of CSA aged 8-17 completed a one-year multimodal treatment program at a dedicated facility known as the Little Warriors Be Brave Ranch. Participants completed self-report outcome measures for PTSD, depression, anxiety, self-esteem, quality of life, family functioning, and substance use at intake and graduation from the program. Changes in reported outcomes for child and youth participants were analyzed over the course of treatment.
resultsA total of 201 sequential individuals who completed the one-year treatment program between January 2022-January 2026, from an initial group of 253 participants, were included in this analysis. Most of the completers were biologically female (n = 166, 82.6%) and were adolescents aged 13-17 (n = 116), while the remainder were children aged 8-12 (n = 85). Overall, positive changes in all outcomes were reported in participants from both groups. The largest effect was reported in adolescent PTSD symptoms (d = 0.94, p < 0.001), depression (d = 0.88, p < 0.001), and anxiety (d = 0.86, p < 0.001). Large effect sizes were also reported in levels of PTSD (d = 0.72, p < 0.001), depression (d = 0.82, p < 0.001), and anxiety (d = 0.64, p < 0.001) in child participants. Participants whose PTSD scores remained above the clinical threshold at graduation had higher levels of family dysfunction, more complex histories of trauma, and lower resilience scores.
conclusionThe findings of this study support the use of a multimodal treatment program for youth CSA survivors. The results suggest that this program design has the capacity to benefit CSA survivors across several domains of mental health and well-being. However, the findings of this study are limited by the lack of a control group. Future research should investigate the long-term effects of treatment, and include comparisons to a control sample, to further elucidate the sustainability of these positive therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.